CXCR5 and colorectal carcinoma: Both CD163 and CD4 + CXCR5 can be regarded as prognostic predictors for CRC patients to facilitate the evaluation of cancer prognosis and TME status, thereby optimizing individualized treatment plans and improving cancer patient survival.